Compare Marsh & McLennan Companies, Inc. (MRSH) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs BIO-TECHNE Corp — how do they compare? Marsh & McLennan Companies, Inc. trades at $180.6 (market cap $87.77B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 7.9× BIO-TECHNE Corp's market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.17%). Which is the better fit depends on your goals.
| MRSH | TECH | |
|---|---|---|
Market Cap | $87.77B | $11.16B |
Sector | Financials | Health |
52-Week High | $211.21 | $72.12 |
52-Week Low | $157.32 | $43.31 |
Enterprise Value | $108.61B | $11.24B |
Dividend Yield | 2.17% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
